MCID: MXD026
MIFTS: 35

Mixed Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Mixed Glioma

MalaCards integrated aliases for Mixed Glioma:

Name: Mixed Glioma 12 55 15
Mixed Gliomas 12 73
Mixed Neuroglial Tumor 12
Glioma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5076
MeSH 44 D005910
NCIt 50 C3903
SNOMED-CT 68 22217002

Summaries for Mixed Glioma

MalaCards based summary : Mixed Glioma, also known as mixed gliomas, is related to glioma and oligodendroglioma. An important gene associated with Mixed Glioma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Photodynamic therapy-induced AP-1 survival signaling. and Central carbon metabolism in cancer. The drugs Gliadel Wafer and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and liver.

Related Diseases for Mixed Glioma

Diseases related to Mixed Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 glioma 30.4 IDH1 PDGFRA TP53
2 oligodendroglioma 29.7 GFAP IDH1 PDGFRA TP53
3 glioma susceptibility 1 29.6 GFAP IDH1 TP53
4 glioblastoma 29.6 IDH1 PDGFRA TP53
5 glioblastoma multiforme 29.4 GFAP IDH1 PDGFRA TP53
6 adult brainstem mixed glioma 12.2
7 oligoastrocytoma 11.5
8 anaplastic oligoastrocytoma 11.2
9 mixed oligodendroglioma-astrocytoma 11.2
10 frontal convexity meningioma 10.2 GFAP TP53
11 gliofibroma 10.2 GFAP TP53
12 cerebral convexity meningioma 10.2 GFAP TP53
13 cellular ependymoma 10.2 GFAP TP53
14 protoplasmic astrocytoma 10.2 GFAP TP53
15 meninges sarcoma 10.2 GFAP TP53
16 central nervous system primitive neuroectodermal neoplasm 10.2 GFAP TP53
17 cerebral neuroblastoma 10.2 GFAP TP53
18 spinal cancer 10.2 GFAP TP53
19 ependymoblastoma 10.2 GFAP TP53
20 cerebral ventricle cancer 10.2 GFAP TP53
21 chordoid glioma 10.2 GFAP TP53
22 malignant ependymoma 10.2 GFAP TP53
23 benign glioma 10.2 GFAP TP53
24 papilloma of choroid plexus 10.2 GFAP TP53
25 choroid plexus cancer 10.2 GFAP TP53
26 necrotizing sialometaplasia 10.2 GFAP TP53
27 cystic teratoma 10.2 GFAP TP53
28 teratoma 10.2 GFAP TP53
29 central nervous system benign neoplasm 10.2 GFAP TP53
30 nervous system benign neoplasm 10.1 GFAP TP53
31 cerebellar liponeurocytoma 10.1 GFAP TP53
32 medullomyoblastoma 10.1 GFAP TP53
33 juvenile pilocytic astrocytoma 10.1 GFAP TP53
34 optic nerve glioma 10.1 GFAP TP53
35 ileum cancer 10.1 GFAP PDGFRA
36 ganglioglioma 10.1 GFAP TP53
37 breast malignant phyllodes tumor 10.1 AGO2 TP53
38 atypical teratoid rhabdoid tumor 10.1 GFAP TP53
39 extraventricular neurocytoma 10.1 GFAP IDH1
40 dysembryoplastic neuroepithelial tumor 10.1 GFAP IDH1
41 intracranial chondrosarcoma 10.1 IDH1 TP53
42 neurilemmoma 10.1 GFAP PDGFRA
43 cerebellar astrocytoma 10.1 IDH1 TP53
44 angiocentric glioma 10.1 GFAP IDH1
45 pilocytic astrocytoma 10.1 GFAP IDH1
46 childhood oligodendroglioma 10.1 GFAP IDH1
47 periosteal osteogenic sarcoma 10.1 IDH1 TP53
48 small cell carcinoma 10.1 PDGFRA TP53
49 cerebellopontine angle tumor 10.1 GFAP IDH1
50 pleomorphic adenoma 10.0 GFAP TP53

Graphical network of the top 20 diseases related to Mixed Glioma:



Diseases related to Mixed Glioma

Symptoms & Phenotypes for Mixed Glioma

Drugs & Therapeutics for Mixed Glioma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Mixed Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
2
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
3
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
4
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
5
Vincristine Approved, Investigational Phase 3,Phase 1 57-22-7, 2068-78-2 5978
6
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
7
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
8
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
10
Ondansetron Approved Phase 3 99614-02-5 4595
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
15
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
16
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
17
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
18
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
19 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
20 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antiemetics Phase 3,Phase 2,Phase 1
23 Emetics Phase 3,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 3,Phase 1
26 Anesthetics, General Phase 3
27 Photosensitizing Agents Phase 3,Phase 2,Phase 1
28 Hematoporphyrin Derivative Phase 3,Phase 2,Phase 1
29 Central Nervous System Depressants Phase 3,Phase 2
30 Dermatologic Agents Phase 3,Phase 2,Phase 1
31 Hematoporphyrins Phase 3,Phase 2,Phase 1
32 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
33 Anesthetics, Inhalation Phase 3
34 Anesthetics Phase 3
35 Ether Phase 3,Phase 2,Phase 1
36 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Autonomic Agents Phase 3,Phase 1
38 BB 1101 Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
40 Cola Phase 3,Phase 1
41 Adjuvants, Anesthesia Phase 3
42 Liver Extracts Phase 3,Phase 2,Phase 1
43 Anesthetics, Intravenous Phase 3
44 Analgesics, Opioid Phase 3
45 Analgesics Phase 3,Phase 2,Phase 1
46 Narcotics Phase 3
47 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
48 Nootropic Agents Phase 3,Phase 2
49 Cholinergic Agents Phase 3,Phase 2
50 Cholinesterase Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
4 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
9 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
10 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
11 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
12 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
13 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Unknown status NCT02238496 Phase 2 Perifosine;Temsirolimus
14 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
15 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
16 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas Completed NCT00003473 Phase 2 Atengenal;Astugenal
17 SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed NCT00004868 Phase 1, Phase 2 semaxanib
18 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
19 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
20 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
21 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
22 Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
23 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
24 Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00047294 Phase 2 celecoxib;temozolomide;thalidomide
25 Fenretinide in Treating Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
26 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
27 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
28 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
29 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
30 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
31 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed NCT01977677 Phase 1, Phase 2 temozolomide;plerixafor
32 Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
33 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
34 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
35 Sunitinib in Treating Patients With Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
36 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
37 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
38 Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
39 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
40 Temozolomide in Treating Patients With Recurrent High-Grade Glioma Completed NCT00619112 Phase 2 temozolomide
41 Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma Completed NCT00005081 Phase 2 O6-benzylguanine;carmustine
42 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Completed NCT00003176 Phase 2 carmustine;temozolomide
43 Immunotoxin Therapy in Treating Patients With Malignant Glioma Completed NCT00006268 Phase 1, Phase 2 isolated perfusion
44 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
45 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
46 ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma Completed NCT00352313 Phase 1, Phase 2 ATN-161;carboplatin
47 Study of Capecitabine to Treat Recurrent High Grade Gliomas Completed NCT00717197 Phase 2 Capecitabine
48 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
49 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
50 Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma Completed NCT00795665 Phase 2 bevacizumab;carmustine

Search NIH Clinical Center for Mixed Glioma

Genetic Tests for Mixed Glioma

Anatomical Context for Mixed Glioma

MalaCards organs/tissues related to Mixed Glioma:

41
Brain, T Cells, Liver, Bone, Spinal Cord, Cerebellum, Myeloid

Publications for Mixed Glioma

Articles related to Mixed Glioma:

(show all 24)
# Title Authors Year
1
Mixed Glioma (Oligoastrocytoma) in the Brain ofA an African Hedgehog (Atelerix albiventris). ( 25172052 )
2014
2
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? ( 25359109 )
2014
3
GFAP-positive neoplastic astrocytes in spontaneous oligodendrogliomas and mixed gliomas of rats. ( 23076037 )
2013
4
Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. ( 12889176 )
2003
5
Diagnosis and management of astrocytomas, oligodendrogliomas and mixed gliomas: a review. ( 11903181 )
2001
6
Long-term outcome of low-grade oligodendroglioma and mixed glioma. ( 10751254 )
2000
7
A histopathological contribution to supratentorial glioma grading, definition of mixed gliomas and recognition of low grade glioma with Rosenthal fibers. ( 10896203 )
2000
8
Exophytic malignant brainstem mixed glioma in an adult: a case report. ( 9524090 )
1998
9
Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours. ( 9524101 )
1998
10
Lectinhistochemistry of mixed gliomas demonstrating an intermediate cell type. ( 9476636 )
1998
11
Glial tumors in the MNU rat model: induction of pure and mixed gliomas that do not require typical missense mutations of p53. ( 9825942 )
1998
12
The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas. ( 7964986 )
1994
13
Low-grade gliomas, mixed gliomas, and oligodendrogliomas. ( 8153667 )
1994
14
The treatment of anaplastic oligodendrogliomas and mixed gliomas. ( 8455760 )
1993
15
Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. ( 1353411 )
1992
16
Mixed gliomas. Their clinical course and results of surgery. ( 3673352 )
1987
17
Combined occurrence of third ventricular germinoma and hypothalamic mixed glioma. ( 3713193 )
1986
18
Spontaneous hemorrhage in a mixed glioma of the cerebellum: case report. ( 3748360 )
1986
19
Mixed glioma of the cerebellopontine angle. ( 3878094 )
1985
20
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. ( 6286891 )
1982
21
Mixed glioma and rhabdomyosarcoma in brain of a wild deer. ( 929897 )
1977
22
Mixed gliomas. ( 4810087 )
1974
23
Mixed glioma, multiple sclerosis, and Charcot-Marie-Tooth disease. ( 5050901 )
1972
24
Subependymal mixed gliomas. ( 13367866 )
1956

Variations for Mixed Glioma

Expression for Mixed Glioma

Search GEO for disease gene expression data for Mixed Glioma.

Pathways for Mixed Glioma

Pathways related to Mixed Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.66 PDGFRA TP53
2 10.61 IDH1 PDGFRA TP53

GO Terms for Mixed Glioma

Biological processes related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 female gonad development GO:0008585 8.62 IDH1 PDGFRA

Sources for Mixed Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....